CN1898268A - 嵌合型抗cd44的抗体和其在治疗急性髓性白血病中的用途 - Google Patents

嵌合型抗cd44的抗体和其在治疗急性髓性白血病中的用途 Download PDF

Info

Publication number
CN1898268A
CN1898268A CNA2004800389743A CN200480038974A CN1898268A CN 1898268 A CN1898268 A CN 1898268A CN A2004800389743 A CNA2004800389743 A CN A2004800389743A CN 200480038974 A CN200480038974 A CN 200480038974A CN 1898268 A CN1898268 A CN 1898268A
Authority
CN
China
Prior art keywords
antibody
cells
seq
chimeric anti
fab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800389743A
Other languages
English (en)
Chinese (zh)
Inventor
F·斯马蒂亚
J·E·迪克
J·卡杜什
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Health Network
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
University Health Network
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Health Network, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical University Health Network
Publication of CN1898268A publication Critical patent/CN1898268A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CNA2004800389743A 2003-11-19 2004-11-19 嵌合型抗cd44的抗体和其在治疗急性髓性白血病中的用途 Pending CN1898268A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03292873.1 2003-11-19
EP03292873A EP1532984A1 (en) 2003-11-19 2003-11-19 Use of anti CD44 antibodies for eradicating stem cells in acute myeloid leukemia

Publications (1)

Publication Number Publication Date
CN1898268A true CN1898268A (zh) 2007-01-17

Family

ID=34429570

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800389743A Pending CN1898268A (zh) 2003-11-19 2004-11-19 嵌合型抗cd44的抗体和其在治疗急性髓性白血病中的用途

Country Status (10)

Country Link
US (4) US20050147606A1 (enExample)
EP (3) EP1532984A1 (enExample)
JP (1) JP2007513610A (enExample)
KR (1) KR20060126659A (enExample)
CN (1) CN1898268A (enExample)
AT (1) ATE480565T1 (enExample)
AU (1) AU2004290918B2 (enExample)
CA (2) CA2484459A1 (enExample)
DE (1) DE602004029078D1 (enExample)
WO (1) WO2005049082A2 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101368173B (zh) * 2008-04-09 2011-12-28 协和干细胞基因工程有限公司 抗人cd44的工程抗体、载体、试剂盒及其用途
CN102741292A (zh) * 2010-02-04 2012-10-17 霍夫曼-拉罗奇有限公司 在治疗头和颈鳞状细胞癌中使用的cd44单克隆抗体
CN111132701A (zh) * 2017-10-25 2020-05-08 锕医药股份有限公司 基于抗-cd45的调理方法及其与基于基因编辑细胞的疗法的联合应用
CN113552363A (zh) * 2020-04-03 2021-10-26 中国科学院广州生物医药与健康研究院 Cd44作为造血干/祖细胞的标志物及其应用
CN114213538A (zh) * 2021-12-24 2022-03-22 北京市神经外科研究所 Cd44抗体、嵌合抗原受体及其应用
CN114316049A (zh) * 2021-12-24 2022-04-12 北京市神经外科研究所 Cd44抗体、嵌合抗原受体及其应用

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071072B2 (en) * 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
EP2783700A1 (en) * 2006-09-07 2014-10-01 Stemline Therapeutics, Inc. Cancer stem cell-targeted cancer therapy
EP2526970A1 (en) * 2006-09-07 2012-11-28 Stemline Therapeutics, Inc. Monitoring cancer stem cells
UY30776A1 (es) * 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
EP2009028A1 (en) * 2007-06-27 2008-12-31 Monoclonal Antibodies Therapeutics Combination of a conventional anti-cancer treatment with anti-CD44 antibody administration for treating solid tumors
AU2010221168A1 (en) * 2009-03-06 2011-10-06 Angstrom Pharmaceuticals, Inc. Compositions and methods for modulation of cell migration
JP2014502258A (ja) * 2010-10-22 2014-01-30 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 免疫反応を抑制するためにプログラムされた制御性ｔ細胞の発見
SG11201401405PA (en) * 2011-10-26 2014-05-29 Univ California Cd44 monoclonal antibody for the treatment of b-cell chronic lymphocytic leukemia and other hematological malignancies
WO2014201417A1 (en) * 2013-06-14 2014-12-18 The University Of Kansas Methods and compositions of modulating tumor initiating cells and the use thereof
NL2011904C2 (en) * 2013-12-06 2015-06-09 Stichting Vu Vumc Leukemic stem cell markers.
EP4103610A1 (en) * 2020-02-13 2022-12-21 UCB Biopharma SRL Anti cd44-ctla4 bispecific antibodies
EP4153192B8 (en) 2020-05-19 2024-09-04 Institut Curie Antagonist of cd44/hyaluronic acid pathway for use in a method for the treatment of cytokine release syndrome
CA3220458A1 (en) 2021-05-18 2022-11-24 Janssen Biotech, Inc. Compositions comprising a t cell redirection therapeutic and an anti-cd44 therapeutic
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024170543A1 (en) 2023-02-14 2024-08-22 Institut National de la Santé et de la Recherche Médicale Anti-cd44 antibodies and uses thereof
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
IL327045A (en) 2023-10-05 2026-05-01 Capstan Therapeutics Inc Structure-restricted ionizable cationic lipids and lipid nanoparticles
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009811A1 (en) * 1992-10-30 1994-05-11 Duke University An adhesion molecule
FR2715664B1 (fr) 1994-01-31 1996-04-12 Proteine Performance Sa Baculovirus recombinant et son utilisation pour la production d'anticorps monoclonaux.
US6492332B1 (en) * 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
EP0826696B1 (de) * 1996-09-03 2002-05-29 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität
JPH10301492A (ja) * 1997-04-23 1998-11-13 Sony Corp 暗号化装置および方法、復号装置および方法、並びに情報処理装置および方法
KR100653803B1 (ko) * 2000-01-21 2006-12-05 소니 가부시끼 가이샤 데이터 처리 시스템 및 데이터 처리 시스템에서의 데이터 처리 방법
TW538636B (en) * 2000-09-01 2003-06-21 Matsushita Electric Industrial Co Ltd Reproduction equipment, reproduction equipment specifying equipment, reproduction equipment specifying system and methods and recording media for said equipment and system
US6972324B2 (en) * 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
DK1401869T3 (da) * 2001-06-01 2008-04-28 Biogen Idec Inc Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101368173B (zh) * 2008-04-09 2011-12-28 协和干细胞基因工程有限公司 抗人cd44的工程抗体、载体、试剂盒及其用途
CN102741292A (zh) * 2010-02-04 2012-10-17 霍夫曼-拉罗奇有限公司 在治疗头和颈鳞状细胞癌中使用的cd44单克隆抗体
CN102741292B (zh) * 2010-02-04 2015-10-21 霍夫曼-拉罗奇有限公司 在治疗头和颈鳞状细胞癌中使用的cd44单克隆抗体
CN111132701A (zh) * 2017-10-25 2020-05-08 锕医药股份有限公司 基于抗-cd45的调理方法及其与基于基因编辑细胞的疗法的联合应用
CN113552363A (zh) * 2020-04-03 2021-10-26 中国科学院广州生物医药与健康研究院 Cd44作为造血干/祖细胞的标志物及其应用
CN113552363B (zh) * 2020-04-03 2024-03-08 中国科学院广州生物医药与健康研究院 Cd44作为造血干/祖细胞的标志物及其应用
CN114213538A (zh) * 2021-12-24 2022-03-22 北京市神经外科研究所 Cd44抗体、嵌合抗原受体及其应用
CN114316049A (zh) * 2021-12-24 2022-04-12 北京市神经外科研究所 Cd44抗体、嵌合抗原受体及其应用
CN114213538B (zh) * 2021-12-24 2022-07-08 北京市神经外科研究所 Cd44抗体、嵌合抗原受体及其应用

Also Published As

Publication number Publication date
EP1692183B1 (en) 2010-09-08
EP2275444A1 (en) 2011-01-19
WO2005049082A3 (en) 2005-11-10
KR20060126659A (ko) 2006-12-08
EP1692183A2 (en) 2006-08-23
DE602004029078D1 (de) 2010-10-21
CA2546566A1 (en) 2005-06-02
AU2004290918B2 (en) 2012-03-08
US20050147606A1 (en) 2005-07-07
WO2005049082A2 (en) 2005-06-02
CA2484459A1 (en) 2005-05-19
US20070237761A1 (en) 2007-10-11
US20070184051A1 (en) 2007-08-09
EP1532984A1 (en) 2005-05-25
ATE480565T1 (de) 2010-09-15
US20100040540A1 (en) 2010-02-18
AU2004290918A1 (en) 2005-06-02
JP2007513610A (ja) 2007-05-31

Similar Documents

Publication Publication Date Title
EP1692183B1 (en) Chimeric anti cd44 antibodies and their use for treating acute myeloid leukemia
AU2010299895B2 (en) Anti-CD33 antibodies and use thereof for immunotargeting in treating CD33-associated illnesses
JP4494977B2 (ja) Ｇｄ２に結合するマウス１４．１８抗体のヒト化抗体（ｈ１４．１８）およびそのｉｌ−２融合タンパク質
CN1200734C (zh) 用表皮生长因子拮抗物治疗顽固性的人肿瘤
KR20220099963A (ko) 세포 수용체를 통한 분자 분해제로서의 조작된 항체
EP3431102A1 (en) Cell injury inducing therapeutic drug for use in cancer therapy
JP2023106392A (ja) Ｃｄ３抗原結合性断片及びその使用
CN113402612A (zh) 靶向cd19和cd20的联合嵌合抗原受体及其应用
AU2011278227B2 (en) Superior efficacy of CD37 antibodies in CLL blood samples
JP6914283B2 (ja) ヒトのがんを治療するための特異的抗ｃｄ３８抗体
JP7682104B2 (ja) 非小細胞肺がんを処置するための方法および組成物
BR112019019597A2 (pt) tratamento de câncer com um anticorpo anti-semaforina- 4d em combinação com um agente de modulação epigenética
EP3929213A1 (en) Anti-pd-l1 antibody and use thereof
WO2023241656A1 (zh) 包含抗cldn18.2抗体的双特异性抗体、药物组合物及用途
EP3915641A1 (en) Anti-cd5 antibodies and methods of use thereof
TW202131950A (zh) 依序抗ｃｄ１９療法
CN107530426A (zh) 癌的治疗和/或预防用药物组合物
TW202019962A (zh) 標靶CD38及TGF-β的組合療法
EP4180457A1 (en) Anti-cldn-18.2 antibody and use thereof
US12077597B2 (en) Anti-CD5 antibodies and methods of use thereof
US20250277037A1 (en) Antibodies specific to pd-1 and methods of use
WO2023236913A1 (zh) 靶向EpCAM的免疫细胞及其医药用途
EP2167544A2 (fr) Antocorps monoclonal dirige contre le recepteur humain des ldl
HK40101629A (zh) 包含抗cldn18.2抗体的双特异性抗体、药物组合物及用途
WO2024007129A1 (zh) 人源化的b7h3抗体或其抗原结合片段

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20070117